rheumatologyadvisor15h
Ustekinumab Has Better Cardiovascular Safety Than Vedolizumab in IBD Management
Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.
Biocon share price in focus after arm launches product in US for autoimmune diseases
Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...
Biocon share price up 2% as arm launches Yesintek in US; check details here
Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...
India Infoline2h
Biocon Biologics introduces stelara biosimilar YESINTEK in US
Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...
pharmaceuticalcommerce13h
Selardsi Launches in the US Market
Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...